Mark White
Mark White is on the board of Annovis Bio, Inc.
He previously was Chief Executive Officer at Neurokine Therapeutics LLC, Senior Director & Group Leader-Pain Therapeutics at Pfizer Inc. and Senior Director-Marketing & Business Development at Bracco Diagnostics, Inc.
Mark White received an undergraduate degree and a graduate degree from the University of Missouri and an MBA from The University of Chicago Booth School of Business.
Transactions
Date
Transaction
Value
| 10/12/2021 | 5,000 | Acquisition at $27.4 per share. | 137,000 |
| 01/31/2020 | 3,252 | Derivative/Non-derivative trans. at $4.8 per share. | 15,609 |
| 01/31/2020 | 34,643 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/31/2020 | 11,548 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/31/2020 | 1,734 | Acquisition at $6 per share. | 10,404 |
